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Note S1 The list of KEGG pathway names, in the same order as in Figure 2A -PYRIMIDINE_METABOLISM  62  -CHEMOKINE_SIGNALING_PATHWAY  63  -GLYOXYLATE_AND_DICARBOXYLATE_METABOLISM  64  -DNA_REPLICATION  65  -PORPHYRIN_AND_CHLOROPHYLL_METABOLISM  66  -NITROGEN_METABOLISM  67  -PYRUVATE_METABOLISM  68  -ARGININE_AND_PROLINE_METABOLISM  69  -PHENYLALANINE_METABOLISM  70  -COMPLEMENT_AND_COAGULATION_CASCADES  71  -VIRAL_MYOCARDITIS  72  -BASAL_CELL_CARCINOMA  73  -CELL_ADHESION_MOLECULES_CAMS 74  -FATTY_ACID_METABOLISM  75  -CITRATE_CYCLE_TCA_CYCLE  76  -P53_SIGNALING_PATHWAY  77  -TAURINE_AND_HYPOTAURINE_METABOLISM  78  -LYSOSOME  79  -HISTIDINE_METABOLISM  80  -SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT  81  -N_GLYCAN_BIOSYNTHESIS  82  -SELENOAMINO_ACID_METABOLISM  83  -FRUCTOSE_AND_MANNOSE_METABOLISM  84  -AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM  85  -CYSTEINE_AND_METHIONINE_METABOLISM  86  -RENIN_ANGIOTENSIN_SYSTEM  87  -STEROID_HORMONE_BIOSYNTHESIS  88  -PRIMARY_BILE_ACID_BIOSYNTHESIS  89  -PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS  90  -VASOPRESSIN_REGULATED_WATER_REABSORPTION  91  -AMYOTROPHIC_LATERAL_SCLEROSIS_ALS  92  -PROTEIN_EXPORT  93  -DRUG_METABOLISM_OTHER_ENZYMES  94  -GLYCOSPHINGOLIPID_BIOSYNTHESIS_GLOBO_SERIES  95  -HEDGEHOG_SIGNALING_PATHWAY  96  -CELL_CYCLE  97  -ASCORBATE_AND_ALDARATE_METABOLISM  98  -NUCLEOTIDE_EXCISION_REPAIR  99  -PENTOSE_PHOSPHATE_PATHWAY  100  -PANTOTHENATE_AND_COA_BIOSYNTHESIS  101  -BUTANOATE_METABOLISM  102  -RIBOFLAVIN_METABOLISM  103  -BASAL_TRANSCRIPTION_FACTORS  104  -ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM  105  -LIMONENE_AND_PINENE_DEGRADATION  106  -GLYCEROLIPID_METABOLISM  107  -VIBRIO_CHOLERAE_INFECTION  108  -VEGF_SIGNALING_PATHWAY  109  -GNRH_SIGNALING_PATHWAY  110  -MELANOGENESIS  111  -AMINOACYL_TRNA_BIOSYNTHESIS  112  -NOTCH_SIGNALING_PATHWAY  113  -PURINE_METABOLISM  114  -HOMOLOGOUS_RECOMBINATION  115  -HYPERTROPHIC_CARDIOMYOPATHY_HCM  116  -GLYCEROPHOSPHOLIPID_METABOLISM  117  -ONE_CARBON_POOL_BY_FOLATE  118  -MISMATCH_REPAIR  119  -GLYCOSAMINOGLYCAN_DEGRADATION  120  -SPHINGOLIPID_METABOLISM  121  -TRYPTOPHAN_METABOLISM  122  -TGF_BETA_SIGNALING_PATHWAY  123  -OOCYTE_MEIOSIS  124  -MAPK_SIGNALING_PATHWAY  125  -VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION  126  -GALACTOSE_METABOLISM  127  -LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION  128  -ADIPOCYTOKINE_SIGNALING_PATHWAY  129  -PROPANOATE_METABOLISM  130  - Figure 1A ,B measures pathway-averaged L tr boxplots (Fig. 1A) pathway-averaged N tr boxplots (Fig. 1B The significantly enriched KEGG pathways are revealed via DAVID gene functional annotation server, taking Homo sapiens as a correction background. The p EASE significance scores for the enrichment are shown along with the number of hit genes. The full list of genes that appear in each enriched pathway can be found in Additional file 3. The gene set is taken from King et al, Nature, 501:58-62, 2013. The genes with summed exon length greater than the all-data median by twice the standard deviation are used. The significantly enriched KEGG pathways are revealed via DAVID gene functional annotation server, taking Homo sapiens as a correction background. The p EASE significance scores for the enrichment are shown along with the number of hit genes. The notations in the brackets mark the pathways linked to cancer (+), neurological (*), cardiological (#) and other (**) multigenic pathological conditions. The full list of genes that appear in each enriched pathway can be found in Additional file 3. The genes with longest transcript length greater than the all-data median by twice the standard deviation are used. The significantly enriched KEGG pathways are revealed via DAVID gene functional annotation server, taking Homo sapiens as a correction background. The p EASE significance scores for the enrichment are shown along with the number of hit genes. The notations in the brackets mark the pathways linked to cancer (+), neurological (*), cardiological (#) and other (**) multigenic pathological conditions. The full list of genes that appear in each enriched pathway can be found in Additional file 3. (equal number) other pathways randomly selected from the available 171. The random selection was done 100000 times, resulting in the above p-value distributions brought in -log 10 scale, where, for instance, the value 4 means p=10 -4 . The dotted vertical lines outline p=0.05 (-log 10 p=1.301), used as a significance threshold. As can be inferred from the figure, such analysis resulted in significant p-values for L tr and N tr 84.9% and 99.8% of times respectively. Please note, that this test is done as a direct demonstration of the absence of the size difference bias in the significance of the shifts between the cancer vs. other distributions. However, the size difference is reflected in the used p-value analyses without the enforced size equalisation, due to the negative (p-value increase) effect of the low data numbers in either of the distributions, reducing the confidence on the corresponding mean value. The density values (y-axes) peak at discrete integer N tr (x-axes), with the intermediate values filled due to the smoothening at the density calculation procedure. The latter has no effect on the p-values that were estimated based on the actual N tr values, independent from the density calculations. The number of genes in both distribution are {133, 9920}, {64, 3383}, {43, 1662}, {40, 954}, {24, 687} and {18, 478} for the plots A-F correspondingly, brought in the {cancer/red, other/blue} format. 
